Commodore Capital LP — 13F Holdings & Portfolio

CIK 1831942 · latest 13F-HR filed 2026-08-14

Commodore Capital LP manages $1.68B in 13F-reported U.S. long-equity assets across 33 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RLAY (13.37%), ELVN (9.90%), ALKS (9.36%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions and exited 8; 15 existing positions rose in reported value and 9 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$1.68B

Long-equity book

Holdings
33

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+5 / −8 / ↑15 / ↓9

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 68.2%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$2.37B
Discretionary
$2.37B
Employees
12
Accounts
3
Address
444 MADISON AVENUE
35TH FLOOR
NEW YORK, NY 10022
Phone
(212) 256-8600
Name Title / Status Ownership Type
Atkinson, Robert Egen, Turrell ControlMANAGING PARTNER
since Jun 2019
Less than 5%Individual
COMMODORE CAPITAL GP LLC ControlGENERAL PARTNER
since Jun 2019
Less than 5%Domestic Entity
Kramarz, Michael, Jonathan ControlMANAGING PARTNER
since Jun 2019
Less than 5%Individual
Bapat, Ameya, VikasCHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, GENERAL COUNSEL
since Mar 2022
Less than 5%Individual
COMMODORE CAPITAL HOLDINGS LPLIMITED PARTNER
since Jun 2019
75% or moreDomestic Entity
Pandya, Anand, BharatCHIEF FINANCIAL OFFICER
since Feb 2023
Less than 5%Individual
Atkinson, Robert Egen, Turrell Control
Indirect owner via COMMODORE CAPITAL HOLDINGS LP
LIMITED PARTNER
since Jun 2019
25–50%Individual
Atkinson, Robert Egen, Turrell Control
Indirect owner via COMMODORE CAPITAL GP LLC
MEMBER
since Jun 2019
25–50%Individual
Kramarz, Michael, Jonathan Control
Indirect owner via COMMODORE CAPITAL HOLDINGS LP
LIMITED PARTNER
since Jun 2019
25–50%Individual
Ownership & leadership changes · 5 filings with changes since Jul 15, 2019

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 31, 2026 filing
  • No longer listedKramarz, Michael, Jonathan · MEMBER · 25–50% · indirect via COMMODORE CAPITAL GP LLC · control person · listed since Jun 2019
Mar 22, 2024 filing
  • ChangedBapat, Ameya, Vikas · title CHIEF COMPLIANCE OFFICER → CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, GENERAL COUNSEL
Mar 24, 2023 filing
  • No longer listedBARAKETT, TIMOTHY, ROBERT · DIRECTOR · General partner, trustee or manager · indirect via COMMODORE CAPITAL GP LLC · listed since Jun 2019
  • No longer listedGLASS, ROBERT, A · CHIEF FINANCIAL OFFICER · Less than 5% · listed since Jun 2019
  • AddedPandya, Anand, Bharat · CHIEF FINANCIAL OFFICER · Less than 5%
  • ChangedAtkinson, Robert Egen, Turrell · indirect via COMMODORE CAPITAL GP LLC: title MEMBER AND DIRECTOR → MEMBER
  • ChangedKramarz, Michael, Jonathan · indirect via COMMODORE CAPITAL GP LLC: title MEMBER AND DIRECTOR → MEMBER
Mar 29, 2022 filing
  • No longer listedHENDERSON, CHRISTINA, MARIE · CHIEF COMPLIANCE OFFICER · Less than 5% · listed since Jun 2019
  • AddedBapat, Ameya, Vikas · CHIEF COMPLIANCE OFFICER · Less than 5%
Mar 30, 2020 filing
  • No longer listedDUBIN, GLENN, RUSSELL · DIRECTOR · General partner, trustee or manager · indirect via COMMODORE CAPITAL GP LLC · listed since Jun 2019
Jul 15, 2019 filing (earliest on record)
  • ListedAtkinson, Robert Egen, Turrell · MANAGING PARTNER · Less than 5% · control person
  • ListedAtkinson, Robert Egen, Turrell · LIMITED PARTNER · 25–50% · indirect via COMMODORE CAPITAL HOLDINGS LP · control person
  • ListedAtkinson, Robert Egen, Turrell · MEMBER AND DIRECTOR · 25–50% · indirect via COMMODORE CAPITAL GP LLC · control person
  • ListedBARAKETT, TIMOTHY, ROBERT · DIRECTOR · General partner, trustee or manager · indirect via COMMODORE CAPITAL GP LLC
  • ListedCOMMODORE CAPITAL GP LLC · GENERAL PARTNER · Less than 5% · control person
  • ListedCOMMODORE CAPITAL HOLDINGS LP · LIMITED PARTNER · 75% or more
  • ListedDUBIN, GLENN, RUSSELL · DIRECTOR · General partner, trustee or manager · indirect via COMMODORE CAPITAL GP LLC
  • ListedGLASS, ROBERT, A · CHIEF FINANCIAL OFFICER · Less than 5%
  • ListedHENDERSON, CHRISTINA, MARIE · CHIEF COMPLIANCE OFFICER · Less than 5%
  • ListedKramarz, Michael, Jonathan · MANAGING PARTNER · Less than 5% · control person
  • ListedKramarz, Michael, Jonathan · LIMITED PARTNER · 25–50% · indirect via COMMODORE CAPITAL HOLDINGS LP · control person
  • ListedKramarz, Michael, Jonathan · MEMBER AND DIRECTOR · 25–50% · indirect via COMMODORE CAPITAL GP LLC · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Commodore Capital LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 RELAY THERAPEUTICS INC RLAY 75943R102 $224.5M 13.37% 12,000,000 SH
2 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $166.2M 9.90% 3,275,000 SH
3 ALKERMES PLC ALKS G01767105 $157.2M 9.36% 3,000,000 SH
4 COGENT BIOSCIENCES INC COGT 19240Q201 $118.0M 7.03% 3,050,000 SH
5 AMYLYX PHARMACEUTICALS INC AMLX 03237H101 $101.5M 6.04% 5,650,000 SH
6 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $94.1M 5.60% 2,000,000 SH
7 SPYRE THERAPEUTICS INC SYRE 00773J202 $75.2M 4.48% 846,786 SH
8 ALTO NEUROSCIENCE INC ANRO 02157Q109 $71.9M 4.28% 2,723,196 SH
9 TANGO THERAPEUTICS INC TNGX 87583X109 $70.3M 4.19% 2,250,000 SH
10 EYEPOINT INC EYPT 30233G209 $65.8M 3.92% 4,600,000 SH
11 TYRA BIOSCIENCES INC TYRA 90240B106 $59.9M 3.57% 1,875,000 SH
12 DAMORA THERAPEUTICS INC DMRA 36322Q206 $50.4M 3.00% 1,939,000 SH
13 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $50.2M 2.99% 1,350,000 SH
14 PHARVARIS N V PHVS N69605108 $49.3M 2.93% 1,425,000 SH
15 LB PHARMACEUTICALS INC LBRX 50180M108 $48.7M 2.90% 1,500,000 SH
16 ASSEMBLY BIOSCIENCES INC ASMB 045396207 $38.9M 2.32% 1,415,000 SH
17 EDITAS MEDICINE INC EDIT 28106W103 $28.8M 1.72% 8,889,000 SH
18 KYMERA THERAPEUTICS INC KYMR 501575104 $28.7M 1.71% 250,000 SH
19 PERSPECTIVE THERAPEUTICS INC CATX 46489V302 $21.6M 1.29% 6,336,782 SH
20 CENTURY THERAPEUTICS INC IPSC 15673T100 $21.3M 1.27% 8,695,652 SH
21 ZURA BIO LTD ZURA G9TY5A101 $19.2M 1.14% 3,250,000 SH
22 AVALO THERAPEUTICS INC AVTX 05338F306 $18.8M 1.12% 1,018,319 SH
23 INFLARX NV IFRX N44821101 $16.4M 0.97% 7,300,000 SH
24 AN2 THERAPEUTICS INC ANTX 037326105 $14.2M 0.85% 2,933,680 SH
25 NUVALENT INC NUVL 670703107 $12.3M 0.74% 100,000 SH
26 SAB BIOTHERAPEUTICS INC SABS 78397T202 $11.2M 0.67% 2,870,000 SH
27 INHIBIKASE THERAPEUTICS INC IKT 45719W205 $11.0M 0.65% 5,397,488 SH
28 RELMADA THERAPEUTICS INC RLMD 75955J402 $9.9M 0.59% 1,425,000 SH
29 PEPGEN INC PEPG 713317105 $8.1M 0.48% 4,475,000 SH
30 RESEARCH ALLIANCE CORP III RACC G75226103 $5.3M 0.32% 500,000 SH
31 HELIX ACQUISITION CORP III HLXC G4444S107 $5.3M 0.32% 500,000 SH
32 LEONABIO INC LONA 04746L203 $4.3M 0.25% 464,398 SH
33 VISTAGEN THERAPEUTICS INC VTGN 92840H400 $630.2K 0.04% 2,788,620 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $1.68B 33 0001831942-26-000033
2026-03-31 2026-05-15 $1.73B 36 0001831942-26-000025
2025-12-31 2026-02-17 $1.50B 33 0001831942-26-000004
2025-09-30 2025-11-14 $2.05B 37 0001831942-25-000023
Filer Information
Address
444 MADISON AVENUE
35TH FLOOR
NEW YORK, NY 10022
Phone
(212) 256-8600
Filing Manager
Commodore Capital LP
NEW YORK, NY
Signatory
Michael Kramarz
Managing Partner